Nationwide recall of cefazolin vials issued
Hanford Pharmaceuticals is voluntarily recalling four lots of Cefazolin for Injection, USP, 1 gm/10 ml vials due to contamination of the active ingredient by Bacillus pumilus, Staphylococcus hominis, Propionibacterium acnes, or Micrococcus luteus. The affected vials were distributed by Sandoz (lots C4650, C4537) and Watson Pharmaceuticals (lots C4689, C4665) and should be promptly returned to Hanford.
Nationwide recall of cefazolin vials issued
Hanford Pharmaceuticals is voluntarily recalling four lots of Cefazolin for Injection, USP, 1 gm/10 ml vials due to contamination of the active ingredient by Bacillus pumilus, Staphylococcus hominis, Propionibacterium acnes, or Micrococcus luteus. The affected vials were distributed by Sandoz (lots C4650, C4537) and Watson Pharmaceuticals (lots C4689, C4665) and should be promptly returned to Hanford. So far, the company has not received any confirmed reports of adverse events related to the recalled lots; however, the contamination could pose a serious or life-threatening risk for some patients. For more information, patients and providers can contact Hanford at (315) 476-7418.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
Challenges for Pharmacies in 2025: What to Expect and How to Prepare
January 8th 2025Pharmacy professionals are used to overcoming obstacles in this competitive, dynamic field. But the coming year will bring challenges affecting patient care, the industry workforce and their business. Pharmacies must be ready to do more than weather the storm; they need deliberate strategy and sophisticated tools to thrive amidst these obstacles. This white paper will discuss the issues and solutions that should be at the top of every pharmacy professional’s mind as they start the new year.
